MX2019000221A - Suministro genetico de sfasl mediado por aav2 como una terapia neuro-protectora en el glaucoma. - Google Patents
Suministro genetico de sfasl mediado por aav2 como una terapia neuro-protectora en el glaucoma.Info
- Publication number
- MX2019000221A MX2019000221A MX2019000221A MX2019000221A MX2019000221A MX 2019000221 A MX2019000221 A MX 2019000221A MX 2019000221 A MX2019000221 A MX 2019000221A MX 2019000221 A MX2019000221 A MX 2019000221A MX 2019000221 A MX2019000221 A MX 2019000221A
- Authority
- MX
- Mexico
- Prior art keywords
- sfasl
- glaucoma
- aav2
- gene delivery
- mediated gene
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 238000001476 gene delivery Methods 0.000 title 1
- 238000011859 neuroprotective therapy Methods 0.000 title 1
- 102400000084 Tumor necrosis factor ligand superfamily member 6, soluble form Human genes 0.000 abstract 3
- 101800000859 Tumor necrosis factor ligand superfamily member 6, soluble form Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 abstract 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662358541P | 2016-07-05 | 2016-07-05 | |
| US201762511629P | 2017-05-26 | 2017-05-26 | |
| PCT/US2017/040735 WO2018009553A1 (en) | 2016-07-05 | 2017-07-05 | Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000221A true MX2019000221A (es) | 2020-02-07 |
Family
ID=60912274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000221A MX2019000221A (es) | 2016-07-05 | 2017-07-05 | Suministro genetico de sfasl mediado por aav2 como una terapia neuro-protectora en el glaucoma. |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20190240353A1 (https=) |
| EP (1) | EP3481433B1 (https=) |
| JP (2) | JP7493334B2 (https=) |
| KR (1) | KR20190096329A (https=) |
| CN (1) | CN110177577A (https=) |
| MX (1) | MX2019000221A (https=) |
| WO (1) | WO2018009553A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3288379T (lt) | 2015-05-01 | 2022-02-25 | Onl Therapeutics, Inc. | Peptidų kompozicijos ir naudojimo būdai |
| WO2019183246A1 (en) * | 2018-03-20 | 2019-09-26 | Onl Therapeutics, Inc. | Compositions and methods of fas inhibition |
| US10862211B2 (en) * | 2018-08-21 | 2020-12-08 | Htc Corporation | Integrated antenna structure |
| US10818758B2 (en) | 2018-11-16 | 2020-10-27 | Asm Ip Holding B.V. | Methods for forming a metal silicate film on a substrate in a reaction chamber and related semiconductor device structures |
| WO2023048529A1 (ko) * | 2021-09-27 | 2023-03-30 | (주) 씨드모젠 | Aav2-f11 단백질을 유효성분으로 포함하는 녹내장 예방 또는 치료용 조성물 |
| WO2023129766A1 (en) * | 2021-12-27 | 2023-07-06 | Onl Therapeutics, Inc. | Sfasl for inhibiting rpe cell death and associated disorders |
| EP4499672A4 (en) * | 2022-03-30 | 2026-04-01 | Univ Pittsburgh Commonwealth Sys Higher Education | Adeno-associated viral vectors for the delivery of nucleic acids to retinal ganglion cells and/or retinal pigment epithelium cells |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
| AU722624B2 (en) | 1996-09-06 | 2000-08-10 | Trustees Of The University Of Pennsylvania, The | An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase |
| US6544523B1 (en) * | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| AU2002248297A1 (en) * | 2001-01-05 | 2002-07-16 | Children's Hospital, Inc. | Aav2 vectors and methods |
| NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
| GB0820262D0 (en) * | 2008-11-05 | 2008-12-10 | Tmo Renewables Ltd | Microorganisms |
| US20140024598A1 (en) * | 2010-11-01 | 2014-01-23 | Demetrios Vavvas | Methods and compositions for preserving retinal ganglion cells |
| US9238679B2 (en) * | 2011-02-11 | 2016-01-19 | The Trustees Of The University Of Pennslyvania | Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same |
| EP2586793A1 (en) * | 2011-10-27 | 2013-05-01 | Centre National de la Recherche Scientifique | Chimeric molecule involving oligomerized FasL extracellular domain |
| US9873747B2 (en) * | 2013-01-31 | 2018-01-23 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| JP6396988B2 (ja) * | 2013-03-15 | 2018-09-26 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 二重グリカン結合性ａａｖベクターのための方法および組成物 |
| WO2015044704A1 (en) * | 2013-09-30 | 2015-04-02 | Sanofi | Use of neuroglobin agonist for preventing or treating mitochondrial rcci and/or rcciii deficiency disease |
-
2017
- 2017-07-05 CN CN201780052351.9A patent/CN110177577A/zh active Pending
- 2017-07-05 EP EP17824815.9A patent/EP3481433B1/en active Active
- 2017-07-05 MX MX2019000221A patent/MX2019000221A/es unknown
- 2017-07-05 US US16/315,362 patent/US20190240353A1/en not_active Abandoned
- 2017-07-05 JP JP2019500483A patent/JP7493334B2/ja active Active
- 2017-07-05 WO PCT/US2017/040735 patent/WO2018009553A1/en not_active Ceased
- 2017-07-05 KR KR1020197003089A patent/KR20190096329A/ko not_active Ceased
-
2022
- 2022-02-18 JP JP2022023711A patent/JP2022084594A/ja active Pending
-
2024
- 2024-03-05 US US18/595,527 patent/US20250001015A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250001015A1 (en) | 2025-01-02 |
| WO2018009553A1 (en) | 2018-01-11 |
| JP2022084594A (ja) | 2022-06-07 |
| US20190240353A1 (en) | 2019-08-08 |
| KR20190096329A (ko) | 2019-08-19 |
| CN110177577A (zh) | 2019-08-27 |
| CA3029864A1 (en) | 2018-01-11 |
| JP7493334B2 (ja) | 2024-05-31 |
| EP3481433A1 (en) | 2019-05-15 |
| EP3481433A4 (en) | 2020-02-26 |
| JP2019520405A (ja) | 2019-07-18 |
| EP3481433B1 (en) | 2024-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000221A (es) | Suministro genetico de sfasl mediado por aav2 como una terapia neuro-protectora en el glaucoma. | |
| MX384192B (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
| PH12017500692A1 (en) | Antibody molecules to pd-l1 and uses thereof | |
| EP3236969A4 (en) | Methods and compositions for treating malignant tumors associated with kras mutation | |
| MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| MX2017007321A (es) | Terapias de combinacion. | |
| HK1220980A1 (zh) | 用於治疗庞贝氏症的方法和组合物 | |
| EP4656246A3 (en) | Combination therapies for the treatment of cancer | |
| EP3303382A4 (en) | Compositions and methods for treating patients with rtk mutant cells | |
| ZA201902320B (en) | 17alpha,21-diesters of cortexolone for use in the treatment of tumors | |
| MX2016002273A (es) | Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib. | |
| MX2017004526A (es) | Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos. | |
| WO2016077639A3 (en) | Nanovesicular therapies | |
| EP3164125B8 (en) | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes | |
| MX377593B (es) | Composiciones para usar en el tratamiento de cáncer renal. | |
| PH12017500809A1 (en) | Improved il-6 antibodies | |
| SG11201607472UA (en) | Multi-player, multi-touch gaming table and method of using the same | |
| PH12016501422B1 (en) | Functionalised benzopyran compounds and use thereof | |
| MX2016011295A (es) | Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2. | |
| MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
| EP3145516A4 (en) | Methods and compositions for treating malignancies with dendritic cells | |
| GB2553439A (en) | Methods for scoring chromosomal instabilities | |
| MX359029B (es) | Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -. | |
| EP3135355A4 (en) | Game delivery device, game delivery method, and game delivery program | |
| MX2016004212A (es) | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. |